600332.SS
600332.SS
CNE000001733
GUANGZHOU BAIYUNSHAN PHARMACEUT
Loading chart...

Company Profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and chemical raw material intermediates; and research, development, production, and sale of health products; and wholesale, retail, and import export of Western medicines, traditional Chinese medicines, and medical devices. The company also offers bio-innovation, consumer health, and medical services; Xiaochaihu granules; Qingkailing and Baoji, Xia Sangju product series; Angong Niuhuang, Zishen Yutai, Xiaoke, Huatuo Zaizao, Zhuangyao Jianshen, and Shujin Jianyao pills; compound Danshen and Naoxinqing tablet series; Banlangen, Compound Banlangen, and Dashen Kouyanqing granules series; and honey-processed Chuanbei and Shedan Chuanbei loquat syrup. In addition, it provides antibacterial and anti-inflammatory drugs, andrological drugs, and analgesics and antipyretics; Wanglaoji herbal tea, Ciningji series, Lixiaoji series, and Yerou coconut milk; and advertising services. Further, the company engages in the medical research industry; technology services industry; leasing and business services; and scientific research and technical services industry. It operates through hospitals, community healthcare facilities, and retail outlets through distributors and agents. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

Related stocks

2607.HK
2607.HK • China
SH PHARMA
11.03 HKD
5.21B USD 1Y -11.4%
600998.SS
600998.SS • China
JOINTOWN PHARMACEUTICAL GROUP C
5.08 CNY
3.83B USD 1Y +3.3%
600511.SS
600511.SS • China
CHINA NATIONAL MEDICINES CORP
26.67 CNY
3.01B USD 1Y -7.4%
0874.HK
0874.HK • China
BAIYUNSHAN PH
13.21 HKD
2.74B USD 1Y -27.9%
1099.HK
1099.HK • China
SINOPHARM
14.87 HKD
5.91B USD 1Y -20.5%
601607.SS
601607.SS • China
SHANGHAI PHARMACEUTICALS HOLDIN
16.68 CNY
9.26B USD 1Y -8.8%
301015.SZ
301015.SZ • China
BAHEAL MEDICAL
25.94 CNY
2.04B USD 1Y -4.5%
600056.SS
600056.SS • China
CHINA MEHECO GROUP CO LTD
9.14 CNY
2.05B USD 1Y -19.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
23.2% p.a.
Max Drawdown (5Y)
-47.2%
Sharpe Ratio (5Y)
-0.46
Beta Factor
0.18
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Historical Stress Test: Maximum peak-to-trough drawdown of -56.3% in the extended horizon.
ende